Tenaya Therapeutics is a clinical-stage biotechnology company dedicated to discovering, designing, developing, and delivering potentially curative gene therapies for heart disease. Their lead programs, TN-201 and TN-401, target MYBPC3-associated hypertrophic cardiomyopathy (HCM) and PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), respectively. They aim to address the underlying drivers of these debilitating conditions to improve and extend the lives of patients and their families.